Literature DB >> 11530798

Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.

S Kinoshita1, A Yoshioka, Y D Park, H Ishizashi, M Konno, M Funato, T Matsui, K Titani, H Yagi, M Matsumoto, Y Fujimura.   

Abstract

Upshaw-Schulman syndrome (USS) is a congenital bleeding disorder characterized by repeated episodes of thrombocytopenia and microangiopathic hemolytic anemia that respond to infusions of fresh frozen plasma. Inheritance of USS has been thought to be autosomal recessive, because 2 siblings in the same family are often affected but their parents are asymptomatic. Recently, chronic relapsing thrombotic thrombocytopenic purpura (CR-TTP), reported almost exclusively in adults, was shown to be caused by inherited or acquired deficiency in the activity of a plasma von Willebrand factor-cleaving protease (vWF-CPase). The pathogenesis of USS is unknown, and a relationship between CR-YEP and USS has not been reported. We studied 3 unrelated USS patients (ST, SY, and KI) who presented with severe indirect neonatal hyperbilirubinemia. All 3 patients had undetectable vWF-CPase activity, and the inhibitors to vWF-CPase were all negative. In their parents with no clinical symptoms, vWF-CPase activities as a percentage of control samples (mother/father) were 17/20 for ST, 60/45 for SY, and 36/5.6 for KI. Thus, USS and vWF-CPase activity appear to be coinherited as autosomal recessive traits. Transfusion of fresh frozen plasma in 2 patients (ST and SY) resulted in the expected maximal increment of approximately 7% to 8% in vWF-CPase activity at 1 to 4 hours, but the levels became less than 3% within 2 days. After this decrease, platelet counts increased, plateaued in the normal range at 10 to 12 days, and declined thereafter. Thus, the 2 to 3 weeks of therapeutic benefit from plasma infusions will be discussed in relation to the intravascular lifetime of vWF-CPase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11530798     DOI: 10.1007/BF02982558

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  26 in total

1.  Letter: A more uniform measurement of factor VIII inhibitors.

Authors: 
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

2.  Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency.

Authors:  I SCHULMAN; M PIERCE; A LUKENS; Z CURRIMBHOY
Journal:  Blood       Date:  1960-07       Impact factor: 22.113

3.  Thrombopoietin in Upshaw-Schulman syndrome.

Authors:  M Miura; S Koizumi; H Miyazaki
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

Review 4.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

5.  Chronic relapsing thrombocytopenic purpura with severe neurological manifestations and full recovery.

Authors:  Y Rabkin; Z Fradin; A Zeidman; A Schwartz; A Cohen; M Mittelman
Journal:  Int J Hematol       Date:  2000-02       Impact factor: 2.490

6.  Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.

Authors:  C A Siedlecki; B J Lestini; K K Kottke-Marchant; S J Eppell; D L Wilson; R E Marchant
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

7.  Fibronectin levels in congenital thrombocytopenia: Schulman's syndrome.

Authors:  L T Goodnough; H Saito; O D Ratnoff
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

8.  Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  M Furlan; R Robles; M Solenthaler; M Wassmer; P Sandoz; B Lämmle
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

9.  Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes.

Authors:  U Budde; R Schneppenheim; H Plendl; J Dent; Z M Ruggeri; T S Zimmerman
Journal:  Thromb Haemost       Date:  1990-04-12       Impact factor: 5.249

10.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.

Authors:  J L Moake; N A Turner; N A Stathopoulos; L H Nolasco; J D Hellums
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

View more
  28 in total

1.  Intensive plasma IgG removal therapy for severe thrombotic thrombocytopenic purpura.

Authors:  Saori Yasuzawa Amano; Masafumi Inoue; Yataro Yoshida; Hideo Yagi; Hiromichi Ishizashi; Masanori Matsumoto; Yoshihiro Fujimura; Akira Yoshioka
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.490

Review 2.  Von Willebrand factor-cleaving protease and Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto; Hideo Yagi; Akira Yoshioka; Taei Matsui; Koiti Titani
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 3.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

4.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

5.  Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome.

Authors:  Yoshihiro Fujimura; Bernhard Lämmle; Saori Tanabe; Kazuya Sakai; Toshiyuki Kimura; Koichi Kokame; Toshiyuki Miyata; Yukihiro Takahashi; Shigeki Taniguchi; Masanori Matsumoto
Journal:  Blood Adv       Date:  2019-11-12

6.  Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).

Authors:  Charles L Bennett; Sony Jacob; Brianne L Dunn; Peter Georgantopoulos; X Long Zheng; Hau C Kwaan; June M McKoy; Jametta S Magwood; Zaina P Qureshi; Nicholas Bandarenko; Jeffrey L Winters; Thomas J Raife; Patricia M Carey; Ravindra Sarode; Joseph E Kiss; Constance Danielson; Thomas L Ortel; William F Clark; Richard J Ablin; Gail Rock; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  Br J Haematol       Date:  2013-03-27       Impact factor: 6.998

7.  Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

8.  ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Sara K Vesely; Spero R Cataland; Paul Coppo; Brian Geldziler; Alfonso Iorio; Masanori Matsumoto; Reem A Mustafa; Menaka Pai; Gail Rock; Lene Russell; Rawan Tarawneh; Julie Valdes; Flora Peyvandi
Journal:  J Thromb Haemost       Date:  2020-09-11       Impact factor: 5.824

Review 9.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

Review 10.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.